Serina Madden, NP
Nurse Practitioner · Oklahoma City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 10 years
- Graduated 2016
Offices
1 location · Ou Health Partners Inc · 1,167 clinicians in this group
Hospitals listed: Ou Health University of Oklahoma Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Serina Madden’s office at (572) 244-0065 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- O U Medical CenterOklahoma City, OKAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of OU Health, which runs 2 hospitalsHome of Stephenson Cancer Center, a National Cancer Institute designated cancer centrePatients rate it 2 of 5 · 64% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.5 (1.27 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — In-hospital fall-associated fracture rate: 0.49 (0.31 to 0.67) · 10,386 cases, Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.71 (5.19 to 8.24) · 3,400 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.55 (14.53 to 24.57) · 1,302 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.6 (5.5 to 7.9) · 1,344 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.198, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.349, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.314, Oct 2024 – Sep 2025
See every measure and the patient survey for O U Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 1 worse of 7 measures. Safety: 3 better, 3 the same, 2 worse of 8 measures. Readmissions: 1 better, 6 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.5 (1.27 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.49 (0.31 to 0.67) · 10,386 cases | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.71 (5.19 to 8.24) · 3,400 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.55 (14.53 to 24.57) · 1,302 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5.5 to 7.9) · 1,344 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.198 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.349 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.314 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.46 (0.68 to 2.25) · 2,646 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 180.85 (143.45 to 218.26) · 284 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.1 · 151 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.2 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 261 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 371 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,857 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.11 to 0.49) · 9,924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.28 (0.79 to 3.77) · 1,346 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.49 to 3.78) · 3,335 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.53 (3.66 to 9.41) · 1,304 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.53 (0.22 to 2.83) · 942 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.51 (0.05 to 0.97) · 9,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 74 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.703 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.055 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 403 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -26.2 · 107 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.1 · 300 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.1 · 415 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 554 cases | None | Jul 2023 – Jun 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.8 (8.5 to 11.4) · 1,344 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.7 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.1 · 264 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.4 to 16.4) · 680 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 967 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,734 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$2,783
Medicare paid this office $2,783 for 34 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 32 | $2,500 | $54 |
Who their Medicare patients are
34 Original Medicare patients in 2024. Average age 55 · Under 65 65% · 85 and older 0% · Also on Medicaid 62% · Health risk score 1.71. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 62% · Depression 35% · Diabetes 32%.
The office billed $21,042, Medicare allowed $3,985 and paid $2,783; for 51 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 34 | 51 | 55 | 1.71 | $21,042 | $2,783 |
| 2021 | 11 | 85 | 54 | 0.98 | $5,750 | $2,492 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Medicaid work
$27,097 in 2024
Medicaid paid $27,097 for 665 billed services this clinician did in 2024, up to 49 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 226 | $16,237 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 66 | $4,812 |
| Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed | 60 | $2,877 |
| T cells; absolute CD4 count | 61 | $912 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 29 | $687 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 29 | $687 |
| COMPREHENSIVE METABOLIC PANEL | 61 | $360 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 60 | $214 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 12 | $167 |
| Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) | 61 | $145 |
| 2024 | 665 | 10 | 49 | $27,097 |
| 2023 | 238 | 4 | 25 | $21,413 |
| 2022 | 166 | 2 | 22 | $15,615 |
| 2021 | 13 | 1 | 13 | $1,267 |
| 2018 | 2,594 | 17 | 100 | $91,080 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 184 | $19,338 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 12 | $936 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 12 | $905 |
| Antibody; HIV-1 and HIV-2, single result | 30 | $233 |
2022
| Return visit (30+ min) | 154 | $15,520 |
| Antibody; HIV-1 and HIV-2, single result | 12 | $95 |
2021
| Return visit (30+ min) | 13 | $1,267 |
2018
| Short return visit (20+ min) | 822 | $46,686 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 194 | $15,709 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 157 | $12,872 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 249 | $4,021 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 117 | $3,011 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 56 | $2,989 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 59 | $1,488 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 97 | $1,297 |
| Service(s) provided in the office during regularly scheduled evening, weekend, or holiday office hours, in addition to basic service | 207 | $1,296 |
| Application of topical fluoride | 118 | $1,127 |
| Screening test, pure tone, air only | 62 | $521 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 14 | $61 |
Drugs they prescribed that Part D paid
$2,028,760
Pharmacies billed $2,028,760 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,064) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
370 generic and 694 brand-name prescriptions · $2,028,760 in drug cost · 71 antibiotic prescriptions to 34 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | 180 | $724,925 | $4,027 |
| Descovy | 220 | $465,518 | $2,116 |
| Triumeq | 57 | $205,622 | $3,607 |
| Prezcobix | 54 | $132,502 | $2,454 |
| Tivicay | 54 | $123,389 | $2,285 |
See all 22 drugs
| Biktarvy | 180 | $724,925 | $4,027 |
| Descovy | 220 | $465,518 | $2,116 |
| Triumeq | 57 | $205,622 | $3,607 |
| Prezcobix | 54 | $132,502 | $2,454 |
| Tivicay | 54 | $123,389 | $2,285 |
| Genvoya | 24 | $102,755 | $4,281 |
| Symtuza | 11 | $47,959 | $4,360 |
| Isentress | 22 | $41,555 | $1,889 |
| Pifeltro | 14 | $26,902 | $1,922 |
| Etravirine | 16 | $19,290 | $1,206 |
| Vemlidy | 13 | $17,267 | $1,328 |
| Emtricitabine-Tenofovir Disop | 20 | $1,871 | $94 |
| Abacavir | 15 | $1,538 | $103 |
| Valganciclovir | 13 | $1,246 | $96 |
| Valacyclovir | 13 | $567 | $44 |
| Doxycycline Hyclate | 29 | $547 | $19 |
| Sulfamethoxazole-Trimethoprim | 34 | $227 | $7 |
| Rosuvastatin | 20 | $172 | $9 |
| Omeprazole | 13 | $130 | $10 |
| Losartan | 15 | $49 | $3 |
| Atorvastatin | 20 | $37 | $2 |
| Amlodipine Besylate | 12 | $20 | $2 |
Year by year
| 2024 | 1,064 | 127 | 0% (0) | 65% | $2,028,760 |
| 2023 | 255 | 33 | 0% (0) | 47% | $271,854 |
| 2022 | 223 | 33 | 0% (0) | 32% | $170,242 |
| 2021 | 155 | 26 | 0% (0) | 37% | $118,179 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Descovy | 95 | $227,402 | $2,394 |
| Emtricitabine-Tenofovir Disop | 13 | $1,693 | $130 |
| Estradiol | 11 | $233 | $21 |
| Testosterone Cypionate | 14 | $159 | $11 |
2022: 4 drugs
| Descovy | 30 | $79,843 | $2,661 |
| Biktarvy | 17 | $63,636 | $3,743 |
| Emtricitabine-Tenofovir Disop | 32 | $2,444 | $76 |
| Lisinopril-Hydrochlorothiazide | 15 | $88 | $6 |
2021: 4 drugs
| Descovy | 18 | $40,480 | $2,249 |
| Biktarvy | 12 | $40,304 | $3,359 |
| Emtricitabine-Tenofovir Disop | 19 | $13,072 | $688 |
| Pravastatin | 11 | $63 | $6 |
Money from drug and device companies
$152 in 2025
| 2025 | 2 | 2 | None | $152 |
| 2024 | 2 | 7 | None | $578 |
| 2023 | 6 | 39 | $1,780 | $3,934 |
| 2022 | 2 | 15 | None | $538 |
| 2021 | 3 | 12 | None | $481 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $132 | 1 payment
|
| ViiV Healthcare | Apretude | $20 | 1 payment
|
See all 2 published payments
| ViiV Healthcare | Meals · 2025-05-05 | Apretude | $20 |
| Gilead Sciences | Meals · 2025-01-22 | None | $132 |
See earlier years (2024, 2023, 2022, 2021)
2024: $578
| Gilead Sciences | Descovy | $503 | 6 payments
|
| ViiV Healthcare | None | $75 | 1 payment
|
2023: $3,934
| Gilead Sciences | Descovy | $3,678 | 25 payments
|
| ViiV Healthcare | Cabenuva | $180 | 10 payments
|
| Abbvie | Mavyret | $28 | 1 payment
|
| Agile Therapeutics | Twirla | $19 | 1 payment
|
| Novo Nordisk | Rybelsus | $16 | 1 payment
|
| Janssen Biotech | Symtuza | $13 | 1 payment
|
2022: $538
| Gilead Sciences | Epclusa | $340 | 8 payments
|
| ViiV Healthcare | Cabenuva | $198 | 7 payments
|
2021: $481
| ViiV Healthcare | Cabenuva | $196 | 3 payments
|
| Gilead Sciences | None | $179 | 4 payments
|
| Janssen Biotech | Symtuza | $106 | 5 payments
|
Professional record
- NPI
- 1548711021
- Licence
- OK 74462
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 507 Piney Oak Dr, Norman, OK, 73072
- NPI first listed
- 2016-10-19
- NPI last updated
- 2026-04-09
- NPI record certified
- 2026-04-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 100 Cambridge St, Boston, MA, 02114 · 20 Foundry St Fl 2, Concord, NH, 03301 · 1900 N Pearl St Ste 1740, Dallas, TX, 75201 · 165 Broadway Fl 23, New York, NY, 10006 · 5600 N May Ave Ste 310, Oklahoma City, OK, 73112 · 195 Page Mill Rd Ste 103, Palo Alto, CA, 94306 · 1000 N West St Ste 1200, Wilmington, DE, 19801